

Information about proposed Board of Directors Annual General Meeting 2018

Proposal for re-election of the current members of the board of directors:

Håkan Björklund

Chairman

Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member and chairman since 2016.

Other appointments: Industry Executive at Avista Capital Partners. Chairman of the Board in Bonesupport AB

Previous appointments: CEO and President of Nycomed. Håkan has served as a Member of the Board of Director of several international life science companies including Alere, Coloplast, Danisco, and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as member of the Board of Directors for Biovitrum.

Shares: 15,800

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Håkan Björklund is proposed for re-election both as member of the board of directors and as chairman of the board.

Annette Clancy

Born 1954. BSc Hons Pharmacology from Bath University UK. Board member since 2014.

Other appointments: Non executive Chairman of the Board of Enyo SA and Lysogene SA. Member of the Board of Directors of Obseva SA.

Previous appointments: Senior Advisor to the Biopharmaceutical Team of Frazier Healthcare Ventures. Chair of the Board of Directors of Genable Therapeutics. Non-Executive Board Director of Silence Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management at GlaxoSmithKline (GSK).

Shares: 3,414

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Matthew Gantz

Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012.

Other appointments: CEO of OxThera AB. Member of the board of Pennsylvania Life Sciences Association and Marine Corps Scholarship Foundation.

Previous appointments: Executive Vice President of BTG Plc., Founder and CEO of Acureon Pharmaceuticals, CEO of Hydrabiosciences Inc., VP Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe, as well as a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Lennart Johansson

Born 1955. MBA from Stockholm School of Economics. Board member since 2010

Other appointments: Member of the management team and Senior Advisor at Patricia Industries (division of Investor AB). Chairman of the board of Fastighets AB Tingshuset 13, board member of Vectura Fastigheter AB, HI3G, Chalmers Ventures, Bonesupport AB, and deputy board member of Mölnlycke Health Care.

Previous appointments: Chairman of the Board of Vectura Fastigheter AB, CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB.

Shares: 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Helena Saxon

Born 1970. MSc from Stockholm School of Economics. Board member since 2011.

Other appointments: CFO at Investor AB. Member of the Board of Directors of SEB.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Shares: 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Hans GCP Schikan

Born 1958. Pharmacist, Utrecht University. Board member since 2011.

Other appointments: Chairman of the Board of Directors of Asceneuron, Switzerland, Interna, The Netherlands and Complix, Belgium. Member of the Board of Directors of Hansa Medical and Wilson Therapeutics, Sweden, Therachon, Switzerland as well as of the Dutch Top Sector Life Sciences & Health, The Netherlands. Advisor to various organisations in Life Sciences & Health

Previous appointments: CEO of Prosensa, Director of the Supervisory Board of Prosensa, Board member of Top Institute Pharma, Chairman of Dutch Association of the Innovative Pharmaceutical Industry, Nefarma. Various senior management positions within previous Organon and Genzyme.

Shares: 4,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Proposal for election of new members of the board of directors:

David Allsop

Born 1963. BSc Hons Chemistry from Coventry University, UK.

Other appointments: Director and sole employee in U-R-NOT Ltd., through which Mr Allsop offers advisory services to the pharma industry.

Previous appointments: David Allsop has more than 30 years' of experience from research as well as marketing within the pharmaceuticals and health care industries. He has international experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Further, Mr. Allsop has experience from successfully launching blockbuster biologics across the entire world. Until January 2018, he was Head of International in Amicus Therapeutics Ltd. Before then Mr. Allsop held a number of senior positions in Biogen 1998–2015.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Elisabeth Svanberg

Born 1961. MD and PhD from the University of Gothenburg, Sweden. Associate professor of surgery.

Other appointments: Chief Development Officer at Ixaltis SA since 2016. Member of the Board of Directors of Follicum AB and PledPharma AB.

Previous appointments: Ms. Svanberg has several years' of experience from a number of positions with a global responsibility within sales, marketing and development of pharmaceuticals. Previously she was Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016 and has worked with Bristol Myers Squibb (BMS) in the US leading the development of a novel diabetes medicine and subsequently served as Head of Medical Affairs for the Intercontinental region. 2000–2007, Ms. Svanberg worked at Serono International in the field of metabolism. Board member of the Swedish American Chamber of Commerce New York.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.